Novartis' Most Advanced Kidney Compound Shows Promise in C3G

Quote
cafead

cafead

Administrator
Staff member
  • cafead   Oct 26, 2020 at 11:22: AM
via Novartis released promising interim Phase II data of iptacopan in C3 glomerulopathy (C3G). The analysis was presented at the virtual American Society of Nephrology (ASN) 2020 Annual Meeting.

article source
 

<



Similar threads

cafead
Despite trial scare, Travere&#039;s Filspari gains full FDA nod in kidney disease showdown with Novartis
Replies
0
Views
31
Pharma/Biotech Companies - In the News
cafead
cafead
cafead
Novartis&#039; Complement Inhibitor Fabhalta Approved for IgAN
Replies
0
Views
50
Pharma/Biotech Companies - In the News
cafead
cafead
cafead
FDA approves Novartis&#039; kidney disease drug
Replies
0
Views
51
Pharma/Biotech Companies - In the News
cafead
cafead
cafead
Novartis, Viatris face new lawsuit over &#039;HeLa&#039; cell misuse claims
Replies
0
Views
31
Pharma/Biotech Companies - In the News
cafead
cafead
cafead
Takeda circles leukemia rival to Novartis&#039; Scemblix in up to $1.3B deal with Ascentage
Replies
0
Views
16
Pharma/Biotech Companies - In the News
cafead
cafead
Top Bottom
Back
Quote